Recent medical studies indicate that individuals using GLP-1 medications, such as Ozempic and Zepbound, may face a heightened risk of developing nonarteritic anterior ischemic optic neuropathy (NAION). This condition can lead to vision loss and is a significant concern for patients on these drugs.
The findings highlight the need for healthcare providers to monitor patients closely for any signs of vision changes. As the use of GLP-1 medications continues to rise, understanding these potential risks is crucial for patient safety and informed treatment decisions.
Patients on GLP-1 medications should schedule regular eye exams to detect early signs of NAION. Healthcare providers must weigh the benefits of weight management against potential vision risks, and patients should report any vision changes immediately.